nimodipine has been researched along with Chronic Illness in 11 studies
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to evaluate the influence of nimodipine on non-migrainous vascular headache in patients with chronic cerebral ischemia." | 9.06 | Nimodipine in the treatment of headache in chronic cerebral ischemia. ( Hadjiev, D; Ivanova, L; Velcheva, I, 1986) |
| "The aim of this study was to evaluate the influence of nimodipine on non-migrainous vascular headache in patients with chronic cerebral ischemia." | 5.06 | Nimodipine in the treatment of headache in chronic cerebral ischemia. ( Hadjiev, D; Ivanova, L; Velcheva, I, 1986) |
| "Ninety-one patients with chronic migraine were randomly divided into four groups: in the control group (group A, 22 cases in total), nimodipine was used in the treatment of chronic migraine for two months; in the infrared polarized light therapy group (group B, 22 cases in total), infrared polarized light was adopted in the treatment of chronic migraine for 50-60d; in the botulinum toxin treatment group (group C, 24 cases in total), ultrasound-and-hyponome-guided type A botulinum toxin was injected into frontal, temporal, and occipital muscles in treating chronic migraine; in the joint treatment group (group D, 23 cases in total), ultrasound-and-hyponome-guided type A botulinum toxin injection in group C and infrared polarized light in group B were both used here in the treatment of chronic migraine." | 2.80 | Efficacy of type a botulinum toxin injections and infrared polarized light on treating chronic migraine. ( Chen, HX; Ding, XD; Hong, Y; Huang, L; Song, JH; Zhang, GB, 2015) |
| "Nimodipine treatment attenuated CCH induced tau phosphorylation by up-regulating expression of miR-132." | 1.48 | Nimodipine attenuates tau phosphorylation at Ser396 via miR-132/GSK-3β pathway in chronic cerebral hypoperfusion rats. ( Chen, Y; Liu, X; Tan, Z; Xie, W; Zhu, Y, 2018) |
| "In aneurysmal subarachnoid haemorrhage cerebral vasospasm leads to clinical worsening and poor outcome." | 1.46 | Clinical Course and Monitoring Parameters After Continuous Interventional Intra-Arterial Treatment in Patients with Refractory Cerebral Vasospasm. ( Doukas, A; Jansen, O; Larsen, N; Mehdorn, M; Stopfer, A; Synowitz, M; von der Brelie, C, 2017) |
| "LPS-infused rats had significant memory deficits in the Morris water maze, and this deficit was ameliorated by treatment with nimodipine." | 1.42 | Calcium dysregulation via L-type voltage-dependent calcium channels and ryanodine receptors underlies memory deficits and synaptic dysfunction during chronic neuroinflammation. ( Adzovic, L; Crockett, AM; D'Angelo, HM; Hopp, SC; Kaercher, RM; Royer, SE; Wenk, GL, 2015) |
| "Nimodipine was administered postoperatively by subcutaneous injection of 1 ml/0." | 1.27 | Intrathecal nimodipine therapy in a primate model of chronic cerebral vasospasm. ( Grace, MG; Lewis, PJ; Nosko, MG; Tanabe, T; Weir, BK, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (45.45) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tan, Z | 1 |
| Chen, Y | 1 |
| Xie, W | 1 |
| Liu, X | 1 |
| Zhu, Y | 2 |
| Li, H | 1 |
| Yang, X | 1 |
| Shi, W | 1 |
| Ma, Z | 1 |
| Feng, G | 1 |
| Wang, Q | 1 |
| Shen, L | 1 |
| Xie, C | 1 |
| Hopp, SC | 1 |
| D'Angelo, HM | 1 |
| Royer, SE | 1 |
| Kaercher, RM | 1 |
| Crockett, AM | 1 |
| Adzovic, L | 1 |
| Wenk, GL | 1 |
| Song, JH | 1 |
| Zhang, GB | 1 |
| Ding, XD | 1 |
| Huang, L | 1 |
| Hong, Y | 1 |
| Chen, HX | 1 |
| von der Brelie, C | 1 |
| Doukas, A | 1 |
| Stopfer, A | 1 |
| Larsen, N | 1 |
| Mehdorn, M | 1 |
| Synowitz, M | 1 |
| Jansen, O | 1 |
| Canadè, V | 1 |
| Catapano, F | 1 |
| Muraca, L | 1 |
| Cosentino, A | 1 |
| Lewis, PJ | 1 |
| Weir, BK | 1 |
| Nosko, MG | 1 |
| Tanabe, T | 1 |
| Grace, MG | 1 |
| Hadjiev, D | 1 |
| Velcheva, I | 1 |
| Ivanova, L | 1 |
| Cosmi, F | 1 |
| Caresia, L | 1 |
| Panebianco, G | 1 |
| Gioia, AE | 1 |
| White, RP | 1 |
| Bakhtian, B | 1 |
| Robertson, JT | 1 |
| Zabramski, J | 1 |
| Spetzler, RF | 1 |
| Bonstelle, C | 1 |
2 trials available for nimodipine and Chronic Illness
| Article | Year |
|---|---|
Efficacy of type a botulinum toxin injections and infrared polarized light on treating chronic migraine.
Topics: Adult; Botulinum Toxins, Type A; Chronic Disease; Cross-Sectional Studies; Disability Evaluation; Fe | 2015 |
Nimodipine in the treatment of headache in chronic cerebral ischemia.
Topics: Aged; Aged, 80 and over; Brain Ischemia; Chronic Disease; Clinical Trials as Topic; Double-Blind Met | 1986 |
9 other studies available for nimodipine and Chronic Illness
| Article | Year |
|---|---|
Nimodipine attenuates tau phosphorylation at Ser396 via miR-132/GSK-3β pathway in chronic cerebral hypoperfusion rats.
Topics: Animals; Apoptosis; Brain Ischemia; Cerebral Cortex; Chronic Disease; Gene Expression Regulation, En | 2018 |
Protective effects of nimodipine on cerebrovascular function in chronic alcoholic encephalopathy.
Topics: Alcohol Amnestic Disorder; Alcohol Drinking; Animals; Arterioles; Cerebellum; Cerebral Arteries; Chr | 2014 |
Calcium dysregulation via L-type voltage-dependent calcium channels and ryanodine receptors underlies memory deficits and synaptic dysfunction during chronic neuroinflammation.
Topics: AIDS-Related Complex; Analysis of Variance; Animals; Calcium; Calcium Channel Blockers; Calcium Chan | 2015 |
Clinical Course and Monitoring Parameters After Continuous Interventional Intra-Arterial Treatment in Patients with Refractory Cerebral Vasospasm.
Topics: Cerebral Angiography; Chronic Disease; Disease Progression; Echoencephalography; Female; Humans; Inf | 2017 |
[Effects of nimodipine on mental deterioration in subjects with chronic cerebrovascular pathology].
Topics: Aged; Aged, 80 and over; Cerebrovascular Disorders; Chronic Disease; Humans; Neurocognitive Disorder | 1991 |
Intrathecal nimodipine therapy in a primate model of chronic cerebral vasospasm.
Topics: Animals; Cerebral Angiography; Chronic Disease; Female; Injections, Spinal; Ischemic Attack, Transie | 1988 |
[Treatment of chronic cerebrovascular insufficiency: comparison of nimodipine and dihydroergotoxine].
Topics: Aged; Cerebrovascular Disorders; Chronic Disease; Dihydroergotoxine; Drug Evaluation; Female; Humans | 1986 |
Evaluation of the efficacy of intrathecal nimodipine in canine models of chronic cerebral vasospasm.
Topics: Animals; Calcium Channel Blockers; Chronic Disease; Disease Models, Animal; Dogs; Female; Injections | 1985 |
Chronic cerebral vasospasm: effect of calcium antagonists.
Topics: Animals; Cerebral Angiography; Chronic Disease; Disease Models, Animal; Dogs; Injections; Ischemic A | 1986 |